CJC-1295 with DAC
CJC-1295 with DAC is a synthetic peptide classified as a Growth Hormone Releasing Hormone (GHRH) analog, developed for advanced research applications. It is designed to bind with GHRH receptors located in the pituitary gland, which plays a central role in regulating the natural production and release of growth hormone (hGH). The inclusion of Drug Affinity Complex (DAC) technology is intended to extend the peptide’s stability and duration of activity in research settings.
Through its mechanism of action, CJC-1295 with DAC is widely studied for its potential to promote sustained growth hormone release over an extended period. Unlike shorter-acting peptides, the DAC modification allows for prolonged interaction with receptors, making it particularly valuable in studies focused on long-term hormone signaling and endocrine function.
Overview
CJC-1295 with DAC is recognized in research for its long-acting properties and its ability to mimic the activity of naturally occurring GHRH. By stimulating pituitary somatotroph cells, it may support increased secretion of growth hormone, which in turn may lead to elevated levels of insulin-like growth factor-1 (IGF-1).
IGF-1 is commonly associated with anabolic processes such as cellular growth, tissue repair, and metabolic regulation. Because of this, CJC-1295 with DAC is frequently explored in studies involving muscle development, bone metabolism, and overall endocrine system performance.
Chemical Profile
-
Peptide Type: Growth Hormone Releasing Hormone (GHRH) Analog
-
Modification: Drug Affinity Complex (DAC)
-
Function: Extended-release growth hormone stimulation
The DAC component plays a key role in extending the peptide’s half-life by enabling binding to plasma proteins, which may allow for a more stable and prolonged presence in research models.
Mechanism of Action
Research suggests that CJC-1295 with DAC may function by binding to GHRH receptors on pituitary cells, triggering intracellular signaling pathways responsible for growth hormone synthesis and release.
The presence of DAC may reduce the rate of peptide breakdown, allowing for continuous receptor activation over time. This sustained signaling effect makes it a preferred compound in studies that require prolonged hormonal stimulation.
Research and Experimental Applications
CJC-1295 with DAC is commonly utilized in laboratory studies focused on:
-
Sustained growth hormone secretion
-
IGF-1 production and hormonal signaling
-
Muscle and bone metabolism
-
Cellular growth and tissue regeneration
-
Metabolic activity and fat metabolism
-
Endocrine system function and regulation
Its extended activity profile makes it particularly useful in experiments that require consistent hormone exposure over longer durations.
Additional Research Insights
In controlled research environments, CJC-1295 with DAC has been associated with prolonged increases in circulating growth hormone levels compared to non-modified peptides. This sustained release pattern may contribute to a more stable hormonal environment in experimental models.
Additionally, its influence on IGF-1 levels has led to further exploration in studies related to protein synthesis, nutrient utilization, and metabolic efficiency. Researchers continue to investigate its broader applications in endocrine and metabolic pathways.
Product Specifications
Storage Instructions
Store CJC-1295 with DAC in a cool, dry place away from direct light. Refrigeration is recommended to maintain stability, particularly after reconstitution in research settings.
Important Notice
CJC-1295 with DAC is intended strictly for research and laboratory use only. It is not approved for human consumption, medical use, or therapeutic applications. All handling must be performed by qualified professionals in accordance with applicable regulations.
